What are CCR4 antagonist drugs?

CCR4 antagonist drugs are pharmacologic agents that share a common mechanism (typically targeting CCR4 (C-C chemokine receptor type 4)). 0 are currently marketed, with 4 more in clinical development.

CCR4 antagonist

0 marketed 3 in Phase 3 1 in Phase 2

This page covers all CCR4 antagonist drugs tracked by Drug Landscape: marketed products and active clinical-stage compounds, targeting CCR4 (C-C chemokine receptor type 4), CCR4.

Targets

CCR4 (C-C chemokine receptor type 4) · CCR4

Phase 3 pipeline (3)

MK-4280 · Merck Sharp & Dohme LLC · Oncology
MK-4280 is a selective antagonist of the chemokine receptor CCR4 that reduces the recruitment and activation of T regulatory cells to the tumor microenvironment.
MK-4280A · Merck Sharp & Dohme LLC · Oncology
MK-4280A is a selective antagonist of the chemokine receptor CCR4 that reduces the recruitment and activation of regulatory T cells and other immune cells to the tumor microenvironment.
MK0831 · Merck Sharp & Dohme LLC · Oncology
MK0831 is a selective antagonist of the chemokine receptor CCR4 that reduces the recruitment and activation of T regulatory cells and other immune cells to the tumor microenvironment.

Phase 2 pipeline (1)

CCX-354-C · Amgen · Immunology
CCX-354-C is a C-C chemokine receptor 4 (CCR4) antagonist that blocks immune cell recruitment to reduce inflammatory responses.